Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 12, 2015 (12 years ago)

Captopril Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet/Capsule Specifications: out of specification for thickness.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA

Affected NDCs 64679-0902-01 64679-0902-02

Compare with the code on your package — it is the most precise check available.

Drug: Captopril

Recalling firm
Wockhardt Usa Inc.
NDC code
64679-902-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0975-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Captopril recalls

See all
Class II · Moderate risk

Captopril Tablets

cGMP Deviations; products being recalled in response to a recall notice from the manufacturer, Wockhardt Limited, following a FDA inspection which noted inadequate investigation of market complaints, resulting in unsuccessful identification of root causes, and the investigation not being expanded to prevent repeat failure

Terminated cGMP deviation Blenheim Pharmacal, Inc. NDC 10544-175-30 D-1109-2015
Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1277-2015
Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1276-2015
Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1275-2015

Other recalls by Wockhardt Usa Inc.

All 2015 recalls
Class III · Low risk

Enalapril Maleate tablets

Failed Impurities/Degradation Specifications: 5mg strength being recalled for out of specification results for related compound.

Terminated Impurity / degradation Wockhardt Usa Inc. D-0051-2018
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: An FDA inspection identified inadequate investigations of past market complaints.

Terminated cGMP deviation Wockhardt Usa Inc. NDC 64679-941-06 D-1347-2015